BiotechTube
Home/Pipeline/SION-638

SION-638

Cystic Fibrosis (F508del mutation)

Phase 1ActiveNCT06132549

Key Facts

Indication
Cystic Fibrosis (F508del mutation)
Phase
Phase 1
Status
Active
Company
Sionna Therapeutics

About Sionna Therapeutics

Sionna Therapeutics is advancing a pipeline of next-generation cystic fibrosis correctors designed to fully restore CFTR function in patients with the prevalent F508del mutation. The company's lead program, SION-638, is in Phase 1 clinical trials, with a portfolio of follow-on candidates targeting distinct mechanisms. Sionna's strategy is to develop combination therapies that could offer superior clinical benefit compared to current standards of care, addressing a significant unmet need in the CF patient population.

View full company profile

Therapeutic Areas

Rare DiseasesPulmonary

Other Cystic Fibrosis (F508del mutation) Drugs

DrugCompanyPhase
SION-109Sionna TherapeuticsPreclinical
SION-451Sionna TherapeuticsPreclinical
SION-676Sionna TherapeuticsPreclinical